Form 4: Cingulate Inc. Director Jeffrey Ervin Granted 15,000 Stock Options

Cingulate Inc. Director Jeffrey S. Ervin was granted 15,000 stock options with an exercise price of $4.14, aligning his interests with shareholder value.

Summary

• Jeffrey S. Ervin, a Director of Cingulate Inc. (CING), was granted 15,000 stock options.
• The options have an exercise price of $4.14 per share.
• The transaction date for the grant was June 20, 2025.
• Each option represents the right to buy one share of Cingulate Inc. Common Stock.
• The options expire on June 20, 2035.
• The options will vest on the earlier of the one-year anniversary of the grant date or the date of Cingulate Inc.'s 2026 annual meeting of stockholders.
• Following this transaction, Mr. Ervin beneficially owns 15,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine event that aligns management interests with shareholders, generally viewed as a neutral to slightly positive development for corporate governance and long-term incentives.

Positives

• The grant of stock options to a director, Jeffrey S. Ervin, aligns his financial interests with the long-term performance and shareholder value of Cingulate Inc.
• The options have a 10-year expiration period (until June 20, 2035), providing a long-term incentive for the director.

Negatives

• No specific negative information is contained within this Form 4 filing, as it primarily reports a routine equity grant.

Risks

• The value of the stock options is dependent on the future market price of Cingulate Inc.'s common stock exceeding the exercise price of $4.14. If the stock price does not rise above this level, the options may expire worthless.
• The options are subject to a vesting schedule, meaning the director cannot fully exercise them until the earlier of the one-year anniversary of the grant date or the 2026 annual meeting of stockholders, introducing a time-based risk to their exercisability.

Future Outlook

The grant of stock options to Director Jeffrey S. Ervin indicates a future alignment of his compensation with the company's stock performance. The options are set to vest on the earlier of the one-year anniversary of the grant date or the 2026 annual meeting of stockholders, suggesting a future point when these options will become exercisable, contingent on the company's performance and his continued service.

Industry Context

This Form 4 filing reflects a common practice in corporate governance where directors and executives are granted equity compensation, such as stock options, to incentivize them to work towards increasing shareholder value. This aligns the interests of the director with those of the company's investors, a standard practice across various industries, including the pharmaceutical or biotechnology sector where Cingulate Inc. operates.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation used across publicly traded companies to align management and board interests with shareholder returns.
• The exercise price of $4.14, which is likely the market price on the grant date, is typical for "at-the-money" options granted as compensation.
• A 10-year expiration period (until June 20, 2035) is a common duration for employee and director stock options, providing a long-term incentive horizon.
• The vesting schedule, tied to either a one-year anniversary or the next annual meeting, is also a standard practice to ensure continued service and performance before the options become fully exercisable.

Related Party Transactions

• The grant of stock options to Director Jeffrey S. Ervin constitutes a transaction with a related party (an insider), which is a standard form of equity compensation.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's interests with shareholders by incentivizing him to increase the company's stock price.

Next Steps

• The stock options will vest on the earlier of the one-year anniversary of the grant date (June 20, 2026) or the date of Cingulate Inc.'s 2026 annual meeting of stockholders.
• Upon vesting, Jeffrey S. Ervin will have the right to exercise these options to purchase common stock at the specified exercise price.

Key Dates

Keywords

Cingulate Inc., CING, SEC Form 4, insider transaction, stock options, equity compensation, director, Jeffrey S. Ervin, beneficial ownership